Cargando…
Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab
BACKGROUND: Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of s...
Autores principales: | Graham, Maya S, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie M, Zhang, Zhigang, Dunphy, Mark P, Kaley, Thomas, Young, Robert J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236386/ https://www.ncbi.nlm.nih.gov/pubmed/32642703 http://dx.doi.org/10.1093/noajnl/vdaa050 |
Ejemplares similares
-
(18)F-FDG Positron Emission Tomography in Multifocal Pyomyositis
por: Harisankar, C. N. B., et al.
Publicado: (2012) -
18F-FDG 18F-FDG Positron Emission Tomography Imaging of Cortical Reorganization in Spinal Trauma
por: Chopra, Jigyasa, et al.
Publicado: (2022) -
Uptake of (18)FDG by a Hepatic Adenoma on Positron Emission Tomography
por: Stephenson, J. A., et al.
Publicado: (2011) -
Metabolic Pattern of Asymptomatic Hip-Prosthesis by 18F-FDG-Positron-Emission-Tomography
por: Beslic, Nermina, et al.
Publicado: (2015) -
The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma
por: Eslick, R, et al.
Publicado: (2017)